Thursday, December 11, 2025, 7:00 PM – 9:00 PM CT (8:00 PM – 10:00 PM ET) | San Antonio, Texas
Cases from the Community: Investigators Discuss the Optimal Role of Endocrine-Based and Other Strategies in the Management of HR-Positive Breast Cancer
Part 3 of a 3-Part CME Satellite Symposium Series
Event Details
Download Webinar Slides
Download Slides (PDF) Download Slides (PPT)
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting
Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom H-L (Third Floor)
Angela DeMichele, MD, MSCE
Mariann T and Robert J MacDonald Professor
in Breast Cancer
Director, Clinical/Translational Research, Solid Tumor Oncology, Hematology/Oncology Division
Co-Leader, Breast Cancer Program
Abramson Cancer Center
Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence
Senior Scholar, Center for Clinical Epidemiology and Biostatistics
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Komal Jhaveri, MD, FACP, FASCO
Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell College of Medicine
New York, New York
Erica Mayer, MD, MPH, FASCO
Director of Breast Cancer Clinical Research
Breast Oncology Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Hope S Rugo, MD
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology
and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California
Professor Emeritus, UCSF
Seth Wander, MD, PhD
Director of Precision Medicine
Termeer Center for Targeted Therapies
Director of Translational Research
Breast Oncology Program
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Moderator
Neil Love, MD
Research To Practice
Miami, Florida
This symposium is sponsored by Research To Practice and supported by grants from Agendia Inc, Biotheranostics Inc, A Hologic Company, Celcuity, Exact Sciences Corporation, Genentech, a member of the Roche Group, Lilly, and Stemline Therapeutics Inc. This is not an official program of the San Antonio Breast Cancer Symposium® (SABCS®️).
Agenda
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting
MODULE 1: Current Role of Genomic Assays in Treatment Decision-Making for Localized Hormone Receptor (HR)-Positive Breast Cancer — Dr DeMichele
- Clinicopathologic factors, such as age, tumor size and grade, and nodal status, affecting the risk of recurrence and the decision to consult a genomic classifier to assist in treatment decision-making for premenopausal and postmenopausal patients with HR-positive, HER2-negative localized breast cancer
- Similarities and differences among available genomic assays (eg, Oncotype DX®, MammaPrint®, Prosigna®, EndoPredict®, Breast Cancer Index®)
- Key studies informing the use of the 21-gene Recurrence Score® (RS) to guide neoadjuvant and adjuvant treatment decision-making for patients with HR-positive, HER2-negative localized breast cancer
- Clinical research supporting the utility of the 70-gene signature in preoperative and adjuvant treatment planning for patients with HR-positive, HER2-negative localized breast cancer
- Current clinical utility of genetic tests and prognostic tools that complement available genomic assays, such as the RSClin educational tool in concert with the 21-gene RS or the BluePrint® molecular subtyping test in concert with the 70-gene signature
- Published research supporting the use of the Breast Cancer Index to inform extended adjuvant endocrine therapy decision-making for patients with HR-positive localized breast cancer
MODULE 2: Role of CDK4/6 Inhibitors and Other Novel Strategies in Therapy for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Jhaveri
- Clinical and biological factors affecting the choice of adjuvant therapy for HR-positive localized breast cancer; rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy for this population
- Extended follow-up, including overall survival results, from the Phase III monarchE trial evaluating the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
- Published findings with adjuvant ribociclib and endocrine therapy compared to endocrine therapy alone in the Phase III NATALEE trial
- FDA-approved indications and identification of appropriate candidates for adjuvant abemaciclib and ribociclib
- Available data with and ongoing studies evaluating CDK4/6 inhibitors as neoadjuvant therapy for localized HR-positive breast cancer
- Emerging positive outcomes from the Phase III lidERA study evaluating giredestrant versus standard adjuvant endocrine treatment for patients with HR-positive, HER2-negative localized breast cancer
MODULE 3: Evolving Up-Front Treatment Paradigm for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Rugo
- Optimal approach to and timing of the assessment of relevant biomarkers for patients with HR-positive mBC; increasing relevance of biomarker evaluation in the up-front setting
- Long-term follow-up from pivotal clinical trials and other relevant research efforts, such as the RIGHT Choice and ABIGAIL trials, evaluating CDK4/6 inhibitors for HR-positive, HER2-negative mBC; factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner
- Key findings from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with HR-positive, HER2-negative mBC with a PIK3CA mutation whose disease had progressed during or within 12 months of adjuvant endocrine therapy
- FDA approval of inavolisib/palbociclib/fulvestrant and clinical role in the treatment of newly diagnosed HR-positive, HER2-negative mBC with a PIK3CA mutation
- Design, eligibility criteria and key endpoints of the Phase III SERENA-6 study evaluating a switch from an aromatase inhibitor to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
- Published findings from SERENA-6; potential role of serial ESR1 testing using circulating tumor DNA and early therapeutic switching in the care of patients found to harbor mutations
MODULE 4: Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr Mayer
- Key efficacy and safety data from the Phase III CAPItello-291 study evaluating capivasertib/fulvestrant for HR-positive, HER2-negative mBC progressing on endocrine therapy with or without a CDK4/6 inhibitor
- FDA approval of capivasertib for patients with PTEN/PI3K/AKT alterations and current role with regard to other evidence-based options
- Mechanistic similarities and differences between gedatolisib and currently approved therapies targeting the PI3K/AKT/mTOR pathway in HR-positive mBC; implications for antitumor activity
- Design, eligibility criteria and primary and secondary endpoints of the Phase III VIKTORIA-1 trial evaluating gedatolisib in combination with fulvestrant with or without palbociclib for patients with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior CDK4/6 inhibitor therapy and an aromatase inhibitor
- Recently presented efficacy and safety findings from the PIK3CA wild-type cohort of VIKTORIA-1; anticipated readout of the PIK3CA-mutated cohort
- Potential role of gedatolisib-containing combination therapy for pretreated HR-positive, HER2-negative mBC that is PIK3CA wild type and PIK3CA mutated
MODULE 5: Current and Future Role of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive mBC — Dr Wander
- Structural and mechanistic similarities and differences between fulvestrant and approved and investigational oral SERDs; implications for antitumor activity, tolerability and ease of use
- Published efficacy and safety results from the Phase III EMERALD trial and real-world datasets evaluating elacestrant for pretreated HR-positive, HER2-negative mBC
- FDA approval of elacestrant for previously treated HR-positive, HER2-negative, ESR1-mutated mBC; optimal incorporation into management algorithms
- Key findings from the Phase III EMBER-3 study of imlunestrant alone or in combination with abemaciclib for patients with HR-positive, HER2-negative mBC pretreated with endocrine therapy with or without a CDK4/6 inhibitor
- Recent FDA approval of imlunestrant monotherapy for HR-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression after at least one line of endocrine therapy; current clinical role
- Recently presented data from the Phase III evERA study of giredestrant in combination with everolimus versus standard endocrine therapy in combination with everolimus for pretreated HR-positive, HER2-negative mBC
- Comparative side-effect profiles of approved and investigational oral SERDs; optimal monitoring for and management of adverse events
CE Information
Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
- Evaluate available research establishing the utility of various genomic assays in personalizing adjuvant systemic therapy for hormone receptor (HR)-positive, HER2-negative breast cancer, and identify patients for whom testing would be clinically useful.
- Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents may be appropriate.
- Review available research documenting the correlation between the presence of various biomarkers (eg, PIK3CA/AKT1/PTEN alterations, ESR1 mutations) and response to specific therapies, and develop optimal testing algorithms for patients with HR-positive metastatic breast cancer (mBC).
- Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for patients with HR-positive mBC to appropriately counsel patients regarding the optimal use of these agents.
- Interrogate published research documenting the efficacy of oral selective estrogen receptor degraders for HR-positive, HER2-negative mBC progressing on endocrine therapy in combination with a CDK4/6 inhibitor in order to optimally integrate these agents into the care of appropriately selected patients.
- Recognize the frequency of PIK3CA/AKT1/PTEN abnormalities in HR-positive mBC, and employ evidence-based approaches designed to target these aberrations for patients with newly diagnosed and relapsed/refractory disease.
- Consider the spectrum, frequency and severity of adverse events associated with various endocrine-based treatment approaches for HR-positive breast cancer, and appreciate strategies to prevent, ameliorate and manage these side effects.
- Recall the design of ongoing clinical trials evaluating novel endocrine-based strategies for HR-positive breast cancer, and appropriately counsel patients about availability and participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr DeMichele — Consulting Agreements: Pfizer Inc; Contracted Research: Genentech, a member of the Roche Group, NeoGenomics, Novartis, Pfizer Inc. Dr Jhaveri — Consultant/Advisory Board Roles: Arvinas, AstraZeneca Pharmaceuticals LP, Bicycle Therapeutics, Blueprint Medicines, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Halda Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Merck, Novartis, Olema Oncology, Pfizer Inc, RayzeBio Inc, Scorpion Therapeutics, Stemline Therapeutics Inc, Zymeworks Inc; Research Funding Support to the Institution: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, RayzeBio Inc, Scorpion Therapeutics, Zymeworks Inc. Dr Mayer — Consulting Agreements: Aktis Oncology, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Novartis. Dr Rugo — Advisory Committees and Consulting Agreements: BioNTech SE, Bristol Myers Squibb, Helsinn Therapeutics (US) Inc, Napo Pharmaceuticals; Contracted Research (Funding to City of Hope): Bicycle Therapeutics, Genentech, a member of the Roche Group, Stemline Therapeutics Inc; Contracted Research (Funding to Prior Institution, UCSF): Ambrx Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc. Dr Wander — Consulting Agreements: Arvinas, AstraZeneca Pharmaceuticals LP, Biovica International AB, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Hologic Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc, Veracyte Inc; Contracted Research: Arvinas, Genentech, a member of the Roche Group, Lilly, Menarini Group, Nuvation Bio, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This activity is supported by educational grants from Agendia Inc, Biotheranostics Inc, A Hologic Company, Celcuity, Exact Sciences Corporation, Genentech, a member of the Roche Group, Lilly, and Stemline Therapeutics Inc.
Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom H-L (Third Floor)
Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2025 San Antonio Breast Cancer Symposium is taking place.
Registration
NOTICE
No fee is charged for this event. Please note that registration for this event is independent of registration for the San Antonio Breast Cancer Symposium.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.
NOTICE:
Registration for this event is independent of registration for SABCS.
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.